FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Go back to FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 197.92 -1.79 (0.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.71 | 52 Week High | $333.65 | |||
| Open | $198.88 | 52 Week Low | $223.02 | |||
| Day High | $201.22 | P/E | 25.34 | |||
| Day Low | $197.84 | EPS | $7.81 | |||
| Volume | 444,956 | |||||
| (NASDAQ: IONS) | Delayed: 76.20 +0.31 (0.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $75.89 | 52 Week High | $62.68 | |||
| Open | $75.89 | 52 Week Low | $19.59 | |||
| Day High | $77.31 | P/E | N/A | |||
| Day Low | $75.77 | EPS | $0.00 | |||
| Volume | 884,033 | |||||
